Dakota Wealth Management Has $1.09 Million Stock Position in Exelixis, Inc. $EXEL

Dakota Wealth Management grew its stake in Exelixis, Inc. (NASDAQ:EXEL) by 97.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,831 shares of the biotechnology company’s stock after purchasing an additional 12,283 shares during the quarter. Dakota Wealth Management’s holdings in Exelixis were worth $1,094,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Hemington Wealth Management raised its stake in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after buying an additional 522 shares during the period. Byrne Asset Management LLC raised its stake in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after buying an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new stake in Exelixis during the 2nd quarter worth $33,000. Bartlett & CO. Wealth Management LLC acquired a new stake in Exelixis during the 1st quarter worth $37,000. Finally, Costello Asset Management INC acquired a new stake in Exelixis during the 1st quarter worth $39,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $39.04 on Friday. The stock has a market capitalization of $10.51 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 0.81 and a beta of 0.32. The business has a 50-day moving average of $38.97 and a 200-day moving average of $39.73. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.Exelixis’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on EXEL shares. Royal Bank Of Canada dropped their price objective on Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 29th. JMP Securities reiterated a “market outperform” rating and set a $50.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Stephens upgraded Exelixis from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Barclays started coverage on Exelixis in a report on Wednesday, September 17th. They set an “equal weight” rating and a $40.00 target price for the company. Finally, Benchmark reiterated a “neutral” rating on shares of Exelixis in a report on Monday, June 23rd. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.